("Scancell" or the "Company")
Director Dealing
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|
|
a) |
|
|
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Fund closely associated with |
|
b) |
Initial notification/Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
|
|
|
b) |
LEI |
2138008RXEG856SNP666 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument |
Ordinary Shares of |
|
b) |
Identification Code |
GB00B63D3314 |
|
c) |
Nature of the transaction |
Purchase of Ordinary Shares |
|
|
|
|
|
d) |
Price(s) and volume(s) |
|
|
e) |
Aggregated information - Aggregated volume - Price |
3,150,000 Ordinary Shares |
|
f) |
Date of the transaction (s) |
|
|
g) |
Place of the transaction |
|
-ENDS-
Scancell (LSE:SCLP; www.scancell.co.uk) is a clinical stage biotechnology company developing targeted off-the-shelf active immunotherapies, to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, the lead product from their DNA ImmunoBody® platform has demonstrated safe, durable and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the lead peptide immunotherapy from their Moditope® platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, Scancell's wholly owned subsidiary,
For more information please contact:
|
|
|
|
|
+44 (0) 20 3709 5700 |
|
|
|
|
Sath Nirmalananthan, CFO |
|
|
|
|
|
Panmure Liberum (Nominated Adviser and Joint Broker) |
+44 (0) 20 7886 2500 |
|
|
|
|
|
|
|
|
+44 (0) 20 3705 9330
|
|
|
|
|
Investor and media relations |
+44 (0) 20 7483 284853 |
|
|
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the